IL6 and osteosarcoma: In this study, we investigated the differential protein expression after recombinant human IL-6 (rhIL-6) intervention before lobaplatin treatment of an osteosarcoma SaOS-2 cell model and revealed potential biomarkers that indicate the decreased sensitivity of osteosarcoma to lobaplatin.